Published in Clin Exp Immunol on May 01, 1985
Production and function of cytokines in natural and acquired immunity to Candida albicans infection. Microbiol Rev (1995) 1.32
Recurrent genital tract infection: a result of induced immunosuppression? Genitourin Med (1989) 1.09
Immune suppression induced by Actinobacillus actinomycetemcomitans: effects on immunoglobulin production by human B cells. Infect Immun (1990) 1.04
A further characterization of Candida albicans-induced suppressor B-cell activity. Immunology (1989) 0.81
Immunosuppressive effects of Prevotella intermedia on in vitro human lymphocyte activation. Infect Immun (1991) 0.78
Immunology of oral candidiasis. J Pharm Bioallied Sci (2014) 0.77
Interleukin 1 and T cell activation. Immunol Rev (1982) 5.00
Purification to apparent homogeneity of murine interleukin 1. J Immunol (1981) 3.33
Lymphocyte suppression in leprosy induced by unique M. leprae glycolipid. Nature (1984) 2.63
Nonspecific inhibitor released by T acceptor cells reduces the production of interleukin-2. Nature (1982) 1.75
Molecular characterization of interleukin 2. Immunol Rev (1982) 1.52
In vivo and in vitro administration of interleukin 2-containing preparation reverses T-cell unresponsiveness in Mycobacterium bovis BCG-infected mice. Infect Immun (1984) 1.44
Human lymphocyte-activating properties of a purified polysaccharide from Candida albicans: B and T cell cooperation in the mitogenic response. J Immunol (1980) 1.44
The relationship between human helper and suppressor factors to a streptococcal protein antigen. J Immunol (1982) 1.43
Soluble suppressor supernatants elaborated by concanavalin A-activated human mononuclear cells. I. Characterization of a soluble suppressor T cell proliferation. J Immunol (1981) 1.34
Generation of suppressor cells in the response of human lymphocytes to a polysaccharide from Candida albicans. J Immunol (1981) 1.31
Hapten-specific T suppressor factor recognizes both hapten and I-J region products on haptenized spleen cells. Nature (1982) 1.28
Candida albicans polysaccharide extract (MPPS) and PPD stimulate the production of interleukin-1 and lymphocyte proliferation. Clin Exp Immunol (1984) 1.05
Suppression of interleukin-2 production by human concanavalin A-induced suppressor cells. Cell Immunol (1984) 0.94
Role of interleukin 1 in antigen-specific T cell proliferation. J Immunol (1984) 0.94
Antigen-specific human T cell factors. II. T cell suppressor factor: biologic properties. J Immunol (1981) 0.92
Induction of interleukin 1 messenger RNA and translation in oocytes. J Immunol (1984) 0.90
Regulation of the human allogenic proliferative response in vitro. II. Production of soluble suppressor factors by suppressor T cells and evidence in favor of "acceptor" cells for suppression among unprimed lymphocytes. Immunogenetics (1981) 0.88
Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab (2001) 6.12
Contact and delayed hypersensitivity in the mouse. I. Active sensitization and passive transfer. Immunology (1968) 5.03
Selective and specific inhibition of 24 hour skin reactions in the guinea-pig. I. Immune deviation: description of the phenomenon and the effect of splenectomy. Immunology (1965) 4.95
Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells. Blood (2001) 3.66
The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin Exp Immunol (2007) 3.51
Depression of the T cell phenomenon of contact sensitivity by T cells from unresponsive mice. Nature (1973) 2.85
Quantitative measurements of T- and B-cell function in "variable" primary hypogammaglobulinaemia: evidence for a consistent B-cell defect. Clin Exp Immunol (1977) 2.62
The role of dendritic cells in the initiation of immune responses to contact sensitizers. I. In vivo exposure to antigen. Cell Immunol (1985) 2.43
Production of immunity and unresponsiveness in the mouse by feeding contact sensitizing agents and the role of suppressor cells in the peyer's patches, mesenteric lymph nodes and other lymphoid tissues. Cell Immunol (1977) 2.40
Suppression of contact sensitivity by T cells in the mouse. I. Demonstration that suppressor cells act on the effector stage of contact sensitivity; and their induction following in vitro exposure to antigen. Proc R Soc Lond B Biol Sci (1974) 2.34
Recombinant interleukin-2 directly augments the cytotoxicity of human monocytes. Nature (1987) 2.31
Contact sensitivity in the mouse. IV. The role of lymphocytes and macrophages in passive transfer and the mechanism of their interaction. J Exp Med (1970) 2.23
Increased prevalence of thyroid autoimmunity in patients successfully treated for Cushing's disease. Clin Endocrinol (Oxf) (2000) 2.19
Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab (1997) 2.14
Suppressor T cells in cell-mediated immunity. Br Med Bull (1976) 2.13
Two mutations of BRCA2 gene at exon and splicing site in a woman who underwent oncogenetic counseling. Ann Oncol (2009) 2.13
Impairment of GH secretion in adults with primary empty sella. J Endocrinol Invest (2002) 2.09
Evidence that celiac disease is primarily associated with a DC locus allelic specificity. Clin Immunol Immunopathol (1983) 2.02
Methodology-dependent variation in documentation of outcome predictors in out-of-hospital cardiac arrest. Acad Emerg Med (1995) 2.01
Subclinical Cushing's syndrome in patients with adrenal incidentaloma: clinical and biochemical features. J Clin Endocrinol Metab (2000) 1.99
Inflammatory lymphoid cells. Cells in immunized lymph nodes that move to sites of inflammation. Immunology (1972) 1.96
Dynamics of a nosocomial outbreak of multidrug-resistant Pseudomonas aeruginosa producing the PER-1 extended-spectrum beta-lactamase. J Clin Microbiol (2001) 1.92
Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia (2004) 1.84
Effectiveness of bystander cardiopulmonary resuscitation and survival following out-of-hospital cardiac arrest. JAMA (1995) 1.83
Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine. J Clin Endocrinol Metab (1993) 1.80
Contact sensitivity in the mouse. XI. Movement of T blasts in the draining lymph nodes to sites of inflammation. Immunology (1973) 1.77
Antigen-mediated depression of delayed hypersensitivity. Br Med Bull (1967) 1.76
Polyarthritis in adults with hypogammaglobulinaemia and its rapid response to immunoglobulin treatment. Br Med J (1976) 1.75
Nonspecific inhibitor released by T acceptor cells reduces the production of interleukin-2. Nature (1982) 1.75
The effect of cyclophosphamide and irradiation on cells which suppress contact sensitivity in the mouse. Clin Exp Immunol (1976) 1.72
Selective and specific inhibition of 24-hour skin reactions in the guinea-pig. II. The mechanism of immune deviation. Immunology (1966) 1.71
Control of adrenergic overactivity by beta-blockade improves the quality of life in patients receiving long term suppressive therapy with levothyroxine. J Clin Endocrinol Metab (1994) 1.69
Prevalence of thyroid diseases in patients with acromegaly: results of an Italian multi-center study. J Endocrinol Invest (2002) 1.65
Induction of cell-mediated immunity in the mouse: circumstantial evidence for highly immunogenic antigen in the regional lymph nodes following skin painting with contact sensitizing agents. Isr J Med Sci (1976) 1.63
Autoantibody production in rabbits. VII. Autoantibodies to gut produced by the injection of bacteria. Immunology (1966) 1.62
Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. J Clin Endocrinol Metab (1999) 1.62
High prevalence of reflux symptoms in duodenal ulcer patients who develop gastro-oesophageal reflux disease after curing Helicobacter pylori infection. Dig Liver Dis (2001) 1.61
Peripheral V gamma 9/V delta 2 T cell deletion and anergy to nonpeptidic mycobacterial antigens in asymptomatic HIV-1-infected persons. J Immunol (1996) 1.60
Dichotomy between immunoglobulin synthesis by cells in gut and blood of patients with hypogammaglobulinaemia. Lancet (1975) 1.60
Prostatic hyperplasia: an unknown feature of acromegaly. J Clin Endocrinol Metab (1998) 1.58
Depressed in vitro peripheral blood lymphocyte response to mitogens in cancer patients: the role of suppressor cells. Int J Cancer (1977) 1.58
Percutaneous computed tomography-guided ethanol injection in aldosterone-producing adrenocortical adenoma. Eur J Endocrinol (1995) 1.56
The molecular basis of alloreactivity. Immunol Today (1990) 1.56
Nonspecific macrophage suppressor factor: its role in the inhibition of contact sensitivity to picryl chloride by specific T suppressor factor. Eur J Immunol (1978) 1.56
The early uptake of radioactive calcium by human lymphocytes treated with phytohaemagglutinin. Immunology (1971) 1.55
Coeliac disease with severe hypogammaglobulinaemia. Gut (1981) 1.55
Contact sensitivity to picryl chloride: the occurrence of B suppressor cells in the lymph nodes and spleen of immunized mice. Cell Immunol (1976) 1.54
Consensus statement: medical management of acromegaly. Eur J Endocrinol (2005) 1.54
Intracellular immunoglobulin production in vitro by lymphocytes from patients with hypogammaglobulinaemia and their effect on normal lymphocytes. Clin Exp Immunol (1976) 1.53
Distribution of immunogenic cells after painting with the contact sensitizers fluorescein isothiocyanate and oxazolone. Different sensitizers form immunogenic complexes with different cell populations. Immunology (1980) 1.53
Identification and function of T cells in the peripheral blood of patients with hypogammaglobulinaemia. Clin Exp Immunol (1974) 1.53
Accuracy of a new monoclonal stool antigen test in post-eradication assessment of Helicobacter pylori infection: comparison with the polyclonal stool antigen test and urea breath test. Dig Liver Dis (2005) 1.52
Lymphocyte purine 5'-nucleotidase edficiency in primary hypogammaglobulinaemia. Lancet (1977) 1.52
The passive transfer of delayed hypersensitivity in the guinea-pig. I. The synergic effect of immune cells and immune serum on the 24-hour skin reaction and a study of the histology. Immunology (1966) 1.51
Anti-haptene T suppressor factor acts through an I-J+, Ly1-2+, T acceptor cell that releases a nonspecific inhibitor of the transfer of contact sensitivity when exposed to antigen. J Immunol (1982) 1.51
Improved cardiovascular risk factors and cardiac performance after 12 months of growth hormone (GH) replacement in young adult patients with GH deficiency. J Clin Endocrinol Metab (2001) 1.51
Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. J Clin Endocrinol Metab (2000) 1.49
Guidelines for acromegaly management. J Clin Endocrinol Metab (2002) 1.48
Depression of delayed hypersensitivity by pretreatment with Freund-type adjuvants. I. Description of the phenomenon. Clin Exp Immunol (1971) 1.47
Escherichia coli antibody: a screening test for immunodeficiency. Br Med J (1974) 1.46
Predictive value of pentagastrin test for preoperative differential diagnosis between C-cell hyperplasia and medullary thyroid carcinoma in patients with moderately elevated basal calcitonin levels. Clin Endocrinol (Oxf) (2009) 1.46
In vivo and in vitro administration of interleukin 2-containing preparation reverses T-cell unresponsiveness in Mycobacterium bovis BCG-infected mice. Infect Immun (1984) 1.44
Dental caries and enamel defects in very low birth weight adolescents. Caries Res (2010) 1.44
Bone loss determined by quantitative ultrasonometry correlates inversely with disease activity in patients with endogenous glucocorticoid excess due to adrenal mass. Eur J Endocrinol (2001) 1.44
Human lymphocyte-activating properties of a purified polysaccharide from Candida albicans: B and T cell cooperation in the mitogenic response. J Immunol (1980) 1.44
Identification and antimicrobial susceptibility testing of clinical isolates of nonfermenting gram-negative bacteria by the Phoenix Automated Microbiology System. New Microbiol (2002) 1.43
Antigen presentation by keratinocytes induces tolerance in human T cells. Eur J Immunol (1990) 1.43
Speculations on the specificity of suppression. Immunol Today (1989) 1.43
Finasteride in the treatment of hirsutism: new therapeutic perspectives. Fertil Steril (1996) 1.43
Peptide analogues as a strategy to induce tolerance in T cells with indirect allospecificity. Transplantation (2000) 1.43
Growth hormone and heart performance. A novel mechanism of cardiac wall stress regulation in humans. Eur Heart J (1997) 1.43
Multispecific T cell response and negative HCV RNA tests during acute HCV infection are early prognostic factors of spontaneous clearance. Gut (2004) 1.42
Immunohistologic analysis of mycobacterial antigens by monoclonal antibodies in tuberculosis and mycobacteriosis. Hum Pathol (1989) 1.41
NOD2/CARD15 in healthy relatives of IBD patients. Eur Rev Med Pharmacol Sci (2006) 1.41
The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Clin Endocrinol (Oxf) (2000) 1.40
Different dysregulations in adrenal steroid biosynthesis as a prevalent cause of hyperandrogenism in women from southern Italy. Fertil Steril (1997) 1.40
Chronic treatment with CV 205-502 restores the gonadal function in hyperprolactinemic males. Eur J Endocrinol (1996) 1.39
Cardiac arrest witnessed by prehospital personnel: intersystem variation in initial rhythm as a basis for a proposed extension of the Utstein recommendations. Ann Emerg Med (1997) 1.39
[Effectiveness of and tolerability to oral desmopressin in the treatment of central diabetes insipidus]. Minerva Med (1992) 1.39
The orbital veins. Am J Ophthalmol (1967) 1.39
Contact sensitivity in the mouse. XII. The use of DNA synthesis in vivo to determine the anatomical location of immunological unresponsiveness to picryl chloride. Immunology (1973) 1.38
Chemotherapy-based control of schistosomiasis haematobia. I. Metrifonate versus praziquantel in control of intensity and prevalence of infection. Am J Trop Med Hyg (1988) 1.38
Translational mini-review series on Th17 cells: induction of interleukin-17 production by regulatory T cells. Clin Exp Immunol (2009) 1.37
In vitro absorption and molecular weight of specific T-cell suppressor factor. Nature (1975) 1.36
Phosphoantigen-reactive Vgamma9Vdelta2 T lymphocytes suppress in vitro human immunodeficiency virus type 1 replication by cell-released antiviral factors including CC chemokines. J Infect Dis (1999) 1.36
Left ventricular diastolic dysfunction in patients with subclinical hypothyroidism. J Clin Endocrinol Metab (1999) 1.36
Contact sensitivity to oxazolone in the mouse. VIII. Demonstration of several classes of antibody in the sera of contact sensitized and unimmunized mice by a simplified antiglobulin assay. Immunology (1972) 1.36
Endoscopic endonasal transsphenoidal approach: outcome analysis of 100 consecutive procedures. Minim Invasive Neurosurg (2002) 1.35
Suppressor cells and the handling of antigen. Immunol Rev (1980) 1.35
Purine metabolism in lymphocytes from patients with primary hypogammaglobulinaemia. Clin Exp Immunol (1978) 1.33
Genetic analysis in Italian families with inflammatory bowel disease supports linkage to the IBD1 locus--a GISC study. Eur J Hum Genet (1999) 1.32
Anergic T cells inhibit the antigen-presenting function of dendritic cells. J Immunol (2000) 1.32
Generation of suppressor cells in the response of human lymphocytes to a polysaccharide from Candida albicans. J Immunol (1981) 1.31
An overview of T-suppressor cell circuits. Annu Rev Immunol (1986) 1.30